Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

J. Weber, M. Mandala, M. Del Vecchio, H.J. Gogas, A.M. Arance, C.L. Cowey,J. Weber, M. Mandala, M. Del Vecchio, H.J. Gogas, A.M. Arance, C.L. Cowey,S. Dalle, M. Schenker, V. Chiarion-Sileni, I. Marquez-Rodas, J.-J. Grob, M.O. Butler,M.R. Middleton, M. Maio, V. Atkinson, P. Queirolo, R. Gonzalez, R.R. Kudchadkar,M. Smylie, N. Meyer, L. Mortier, M.B. Atkins, G.V. Long, S. Bhatia, C. Lebbé,P. Rutkowski, K. Yokota, N. Yamazaki, T.M. Kim, V. de Pril, J. Sabater, A. Qureshi,J. Larkin, and P.A. Ascierto, for the CheckMate 238 Collaborators*